WebThe ILD Clinic at Duke is participating in several multi-center clinical trials to test new and promising medications for treatment of IPF. Current Clinical Trials Each study has specific pulmonary function, radiographic, pathologic, and disease history requirements. A surgical lung biopsy is often not required. WebApr 11, 2024 · The study enrolled a total of 372 people with IPF, ages 40-85, who were not currently using any approved IPF treatments. Trial participants will be randomly assigned …

Zephyrus I: Evaluation of Efficacy and Safety of …

WebApr 3, 2024 · IPF is a fatal progressive disease, and patients need new treatment options to improve their clinical outcomes.” Pamrevlumab is currently in Phase III clinical development to treat locally advanced unresectable pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD), in addition to IPF. WebMar 30, 2024 · open to eligible people ages 40-85. This is a Phase 3 trial to evaluate the efficacy and safety of 30 milligrams (mg)/kilogram (kg) intravenous (IV) infusions of pamrevlumab administered every 3 weeks as compared to placebo in participants with Idiopathic Pulmonary Fibrosis (IPF).…. San Francisco, California and other locations. inteletravel hyperwallet.com login

Pamrevlumab Trials FibroGen

WebSep 1, 2024 · Based on these positive findings, PRAISE was initiated. 103 patients with IPF per current guidelines, with FVC ≥55% predicted, DLCO ≥30% predicted and between … WebDOI: 10.1177/1060028020964451 Abstract Background: The comparative efficacy of pirfenidone, nintedanib, and pamrevlumab in slowing the rate of forced vital capacity (FVC) decline and mortality in patients with idiopathic pulmonary fibrosis (IPF) is unknown. Objective: To perform a systematic review and meta-analysis (MA) of these drugs for IPF. WebPamrevlumab was effective and safe in patients in a placebo-controlled phase 2 trial, demonstrating its potential to become an alternative therapeutic option for IPF; however, … intel ethernet windows 10